Systemic vasculitis: a modern view on the problem

The aim of the study was to summarize the literature data on various types of systemic vasculitis, their mechanisms of development, diagnostic possibilities, and to describe a clinical case. Systemic vasculitis is a group of diseases with heterogeneous etiology, which involve vessels of different calibers, predominantly small and/or medium, manifesting as multi-organ dysfunction, difficult to treat, and with a poor prognosis. Currently, the following types are distinguished: large vessel vasculitis; medium vessel vasculitis; small vessel vasculitis; variable vessel vasculitis; single-organ vasculitis; vasculitis associated with systemic diseases; vasculitis associated with specific etiology. In the clinic of internal medicine, kidney involvement (glomeruloand tubulopathies, renal insufficiency), skin (ulcerative-necrotic and trophic changes), lungs (interstitial involvement, respiratory insufficiency, recurrent pneumonias), and central nervous system (acute ischemic events, thromboses, polyneuropathies, cognitive disorders, gait disturbances), heart (myocarditis with heart failure) are most commonly encountered. Systemic vasculitis most often manifests in winter and spring periods. Hemorrhagic vasculitis and Kawasaki disease are most commonly seen among children and young adults. In the post-COVID era, systemic vasculitis has been detected more frequently. The study presents the results of personal observation of a patient suffering from infectious-toxic systemic vasculitis.

1. Beketova T.V., Nasonov E.L. Current trends in classification and treatment of systemic vasculitis associated with anti-neutrophilic cytoplasmic antibodies: results of 2011. Terapevticheskii arkhiv.2012;84:5:68–74. (In Russian).

2. Mukhin N.A., Novikov P.I., Moiseev S.V., Semenkova E.N., Kozlovskaya L.V., Fomin V.V., Lopatina I.A. Eff ektivnost’ i bezopasnost’ genno-inzhenernykh biologicheskikh preparatov u patsientov s revmatoidnym artritom i drugimi revmaticheskimi zabolevaniyami (prospektivnoe nekontroliruemoe issledovanie). Klinicheskaya farmakologiya i terapiya. 2012;21(5):25–32. (In Russian).

3. Guseva N.G., Nasonova Y.A., Ivanova M.M. Academician Eugeny Mihailovich Tareev and significance of his ideas in modem rheumatology. Rheumatology Science and Practice. 2008;46(6):86– 91. (In Russian). DOI: 10.14412/1995-4484-2008-496

4. Chuchalin A.G. Primary systemic and pulmonary vasculitis. RMJ. 2001;21:912. (In Russian).

5. Beketova T.V., Golovina O.A., Avdeeva A.S. Cli ni cal and immunological variants of ANCA-associated systemic vas culitis: a look at the pulmonary fibrosis in microscopic polyangiitis with antimyeloperoxidase antibodies and rheumatoid factor. Litera ture review and own observation. Rheumatology Science and Practice. 2023; 61(1):62–69. (In Russian). DOI: 10.47360/1995-4484-2023-62-69

6. La Rocca G., Del Frate G., Delvino P., Di Cianni F., Moretti M., Italiano N. et al. Systemic vasculitis: one year in review 2022. Clin. Exp. Rheumatol. 2022;40(4):673–687. DOI: 10.55563/clinexprheumatol/ozhc85

7. Baranov A.A. Systemic vasculitis: modern standards of diagnosis and treatment. RMJ. 2005;24:1577. (In Russian.)

8. Monti G., Saccardo F., Castelnovo L., Novati P., Sollima S., Riva A. et al. Prevalence of mixed cryoglobulinaemia syndrome and circulating cryoglobulins in a population-based survey: the Origgio study. Autoimmun. Rev. 2014;13(6):609–14. DOI: 10.1016/j.autrev.2013.11.005

9. Ignatova T.M., Kozlovskaya L.V., Gordovskaya N.B., Chernova O.A., Milovanova S.Y., Novikov P.I. et al. Hepatitis C virus-associated cryoglobulinemic vasculitis: A 20-year experience with treatment. Terapevticheskii arkhiv. 2017;89:5:46–52. (In Russian). DOI: 10.17116/terarkh201789546-52

10. Desbois A.C., Cacoub P., Saadoun D. Cryoglobulinemia: An update in 2019. Joint Bone Spine. 2019;86(6):707–713. DOI: 10.1016/j.jbspin.2019.01.016

11. Kolopp-Sarda M.N., Miossec P. Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis. Curr. Opin. Rheumatol. 2021;33(1):1–7. DOI: 10.1097/BOR.0000000000000757

12. Muhin N.A., Kozlovskaya L.V., Milovanova L.Yu., Tegai S.V., Gordovskaya N.B., Ignatova T.M., Kudlinskii I.S. HCV-associated cryoglobulinemic vasculitis with severe kidney damage and the development of B-cell lymphoma. Modern possibilities of changing the prognosis using monoclonal antibodies to CD20 and antiviral therapy. Klinicheskaya nefrologiya. 2011;2:61–69. (In Russian).

13. Retamozo S., Quartuccio L., Ramos-Casals M. Cryoglobulinemia. Med. Clin. (Barc). 2022;158(10):478–487. English, Spanish. DOI: 10.1016/j.medcli.2021.11.017

14. Golovach I.Yu., Yegudina Y.D. Cryoglobu linemia and cryoglobulinemic vasculitis: etiological aspects and pathophysiological associations. Modern Rheumatology Journal. 2020;14(1):78–84. (In Russian). DOI: 10.14412/1996-7012-2020-1-78-84

15. Zakharova E.V. ANCAassociated and cryoglobulinemic vasculitis: diagnosis and treatment (Literature review). Nephrology and dialysis. 2005;7(1):6–25. (In Russian).

16. Palshina S.G., Vasil’ev V.I. Krioglobulinemicheskiy vaskulit. Rheumatology Science and Practice. 2010;48(4):59–66. (In Russian). DOI: 10.14412/1995-4484-2010-1167

17. Roccatello D., Saadoun D., Ramos-Casals M., Tzioufas A.G., Fervenza F.C., Cacoub P., Zignego A.L., Ferri C. Cryoglobulinaemia. Nat. Rev. Dis. Primers. 2018;4(1):11. DOI: 10.1038/s41572-018-0009-4

18. Guo S., Wietecha T.A., Hudkins K.L., Kida Y., Spencer M.W., Pichaiwong W., Kojima I., Duffield J.S., Alpers C.E. Macrophages are essential contributors to kidney injury in murine cryoglobulinemic membranoproliferative glomerulonephritis. Kidney Int. 2011;80(9):946–958. DOI: 10.1038/ki.2011.249

19. Menegatti E., Messina M., Oddone V., Rubini E., Sciascia S., Naretto C., Baldovino S., Roccatello D. Immunogenetics of complement in mixed cryoglobulinaemia. Clin. Exp. Rheumatol. 2016;34(3–97):S12–S15.

20. Milovanova S.Yu., Lysenko (Kozlovskaya) L.V., Milovanova L.Yu., Abdurahmanov D.T., Taranova M.V., Volkov A.V. Cryoglobulinemic vasculitis associated with HCV infection: still a problem? Nephrology (Saint Petersburg). 2022;26(3):30–39. (In Russian). DOI: 10.36485/1561-6274-2022-26-3-30-39

21. Elbendary A., Abdel-Halim M.R.E., Ragab G. Updates in cutaneous manifestations of systemic vasculitis. Curr. Opin. Rheumatol. 2022;34(1):25–32. DOI: 10.1097/BOR.0000000000000847

22. DeHoratius D.M. Cutaneous small vessel vasculitis. Postgrad. Med. 2023;135(1):44–51. DOI: 10.1080/00325481.2022.2159207

23. Andreo Galera M., Lidón Pérez F., Falcón Vega S., Gutiérrez Rodero F. Cutaneous Vasculitis. Med. Clin. (Barc). 2023;160(7):326. English, Spanish. DOI: 10.1016/j.medcli.2022.11.002

24. Misra D.P., Thomas K.N., Gasparyan A.Y., Zimba O. Mechanisms of thrombosis in ANCA-associated vasculitis. Clin. Rheumatol. 2021;40(12):4807–4815. DOI: 10.1007/s10067-021-05790-9

25. Springer J., Villa-Forte A. Thrombosis in vasculitis. Curr. Opin. Rheumatol. 2013;25(1):19–25. DOI: 10.1097/BOR.0b013e32835ad3ca

26. Podchernyaeva N.S., Kostina Y.O., Kasanave E.V., Shpitonkova O.V., Korotkova E.A. Livedoid vasculopathy in adolescents. Pediatria. 2017; 96 (3): 210– 213. (In Russian). DOI: 10.24110/0031-403X-2017-96-3-210-213

27. Beketova T.V., Solovyev S.K., Radenska-Lopovok S.G., Nasonov E.L. Livedoid vasculopathy: experience in using rituximab. Rheumatology Science and Practice. 2011;49(4):78–81. (In Russian). DOI: 10.14412/1995-4484-2011-66

28. Soulages A., Maisonobe T., Auzou P., Petit A., Allenbach Y., Barète S. et al. Peripheral neuropathy and livedoid vasculopathy. J. Neurol. 2022;269(7):3779–3788. DOI: 10.1007/s00415-022-11007-z

29. Song X., Tu P. Treatment of livedoid vasculopathy with baricitinib. JAMA Dermatol. 2022;158(5):587–589. DOI: 10.1001/jamadermatol.2022.0241

30. Gao Y., Jin H. Livedoid vasculopathy and peripheral neuropathy: A retrospective cohort study of 55 Chinese patients and literature review. Int. Wound J. 2023;20(5):1498–1505. DOI: 10.1111/iwj.14004

31. Khenifer S., Thomas L., Balme B., Dalle S. Livedoid vasculopathy: thrombotic or inflammatory disease? Clin. Exp. Dermatol. 2010;35(7):693–8. DOI: 10.1111/j.1365-2230.2009.03732.x

32. Marzano A.V., Vanotti M., Alessi E. Widespread livedoid vasculopathy. Acta Derm. Venereol. 2003;83(6):457–60. DOI: 10.1080/00015550310015455

33. Toth C., Trotter M., Clark A., Zochodne D. Mononeuropathy multiplex in association with livedoid vasculitis. Muscle Nerve. 2003 Nov;28(5):634 –9. DOI: 10.1002/mus.10450

34. Murkamilov I.T., Aitbaev K.A., Fomin V.V., Kudaibergenova I.O., Yusupov F.A., Murkamilova Z.A., Beketova T.V. Microscopic polyangiitis: Modern concepts and treatment options. Rheumatology Science and Practice. 2021;59(5):608–614. (In Russian). DOI: 10.47360/1995-4484-2021-608-614

35. Murkamilov I., Aitbaev K., Fomin V., Yusupov F., Murkamilova Zh. Polyarteritis nodosa: prevalence, risk factors, and treatment options (literature review and clinical observation). The scientific heritage. 2020;47–2(47):31–39. (In Russian).

36. Hoffman G.S., Calabrese L.H. Vasculitis: determinants of disease patterns. Nat. Rev. Rheumatol. 2014;10:454–462. https://doi.org/10.1038/nrrheum.2014.89

37. Suffredini D.A., Cui X., Xu W., Li Y., Eichacker P.Q. The potential pathogenic contributions of endothelial barrier and arterial contractile dysfunction to shock due to b. anthracis lethal and edema toxins. Toxins (Basel). 2017 6;9(12):394. DOI: 10.3390/toxins9120394

38. Negrey J.D., Behringer V., Langergraber K.E., Deschner T. Urinary neopterin of wild chimpanzees indicates that cell-mediated immune activity varies by age, sex, and female reproductive status. Sci. Rep. 2021;11(1):9298. DOI: 10.1038/s41598-021-88401-6

39. Lubkin A., Torres V.J. Bacteria and endothelial cells: a toxic relationship. Curr. Opin. Microbiol. 2017;35:58–63. DOI: 10.1016/j.mib.2016.11.008

40. Soupotnitsky M.V. Bacterial toxins. Their nature, modes of action, opportunities of creating hybrid and modified toxins. Biopreparats (Biopharmaceuticals). 2011;1:6–15. (In Russian).

41. Peng L., Jiang J., Chen T., Xu D., Hou F., Huang Q. et al. Toxic shock syndrome toxin 1 induces immune response via the activation of NLRP3 inflammasome. Toxins (Basel). 2021;13(1):68. DOI: 10.3390/toxins13010068

42. Cullen C.M., Bonventre P.F., Heeg H., Bluethmann H., Mountz J.D., Edwards C.K 3rd. A fas antigen receptor mutation allows development of toxic shock syndrome toxin-1-induced lethal shock in V beta 8.2 T-cell receptor transgenic mice. Pathobiology. 1995;63(6):293–304. DOI: 10.1159/000163965

43. Cameron S.B., Nawijn M.C., Kum W.W., Savelkoul H.F., Chow A.W. Regulation of helper T cell responses to staphylococcal superantigens. Eur. Cytokine Netw. 2001;12(2):210–22.

44. Zakharova E.V., Makarova T.A., Leo nova E.S., Stolyarevich E.S., Vorobyova O.A. Diagnostics of kidney damage in the medium and large vessels vasculitis — review and presentation of three cases. Nephrology and dialysis. 2020 ;22(1):108–130. (In Russian). DOI: 10.28996/2618-9801-2020-1-108-130

45. Gordovskaia N.B., Kozlovskaia L.V., Milovanova S.Iu. Cryoglobulinemic vasculitis with renal involvement: A historic aspect of the problem. Terapevticheskii Arkhiv. 2015;87(6):112–117. (In Russian). DOI: 10.17116/terarkh2015876112-117

46. Strizhakov L.A., Moiseev S.V., Semenkova E.N., Kuznetsova E.I. Cardiovascular complications and endothelial dysfunction in primary vasculitis. Terapevticheskii arkhiv. 2012;84:5:31–35. (In Russian).